Table 1 Patients characteristics
From: Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts
|  | All n = 209 | BRAFV600E/K n = 54 | BRAFwt n = 136 | BRAFOther n = 19 | χ2 |
|---|---|---|---|---|---|
Age distribution | 0.056 | ||||
 ≤ 60 | 26% | 40% | 22% | 20% |  |
 61–75 | 35% | 31% | 37% | 30% |  |
 > 75 | 39% | 29% | 41% | 50% |  |
Gender | 0.913 | ||||
 Female | 40% | 61% | 59% | 35% |  |
 Male | 60% | 39% | 41% | 65% |  |
Tumor localization | 0.002 | ||||
 Trunk | 28% | 44% | 21% | 30% |  |
 Lower extremity | 32% | 32% | 36% | 10% |  |
 Upper extremity | 12% | 9% | 14% | 5% |  |
 Head/neck | 28% | 15% | 29% | 55% |  |
Histological subtype | < 0.0001 | ||||
 SSM | 37% | 56% | 32% | 20% |  |
 NM | 24% | 32% | 19% | 35% |  |
 LMM | 10% | 0 | 10% | 35% |  |
 ALM | 18% | 11% | 24% | 0 |  |
 Others | 11% | 2% | 15% | 10% |  |
Tumor thickness | 0.223 | ||||
 1.01–2.0 mm | 14% | 15% | 15% | 5% |  |
 2.01–4.0 mm | 53% | 52% | 50% | 75% |  |
 > 4 mm | 33% | 33% | 35% | 20% |  |
Ulceration | 0.987 | ||||
 Yes | 62% | 61% | 62% | 65% |  |
 No | 38% | 39% | 38% | 35% |  |
Regression | 0.001 | ||||
 Yes | 14% | 18% | 11% | 20% |  |
 No | 70% | 80% | 65% | 80% |  |
 N/A | 16% | 2% | 24% | 0 |  |
Stage at initial diagnosis | 0.885 | ||||
 IIA | 43% | 44% | 43% | 40% |  |
 IIB | 33% | 32% | 33% | 40% |  |
 IIC | 24% | 24% | 24% | 20% |  |